Artículo de revista
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo- controlled, phase 3 trial
Registro en:
10.1016/S1470-2045(23)00052-9
Autor
Monk, BJ; Tewari, KS; Dubot, C; Caceres, MV; Hasegawa, K; Shapira-Frommer, R; Salman, P; Yanez, E; Guemues, M; Mendoza, MOHD; Samouelian, V; Castonguay, V; Arkhipov, A; Tekin, C; Li, K; Nguyen, AM; Monberg, MJ; Colombo, N; Lorusso, D